Biochromatics Video Presentation
USING BIOCHROMATIC SIGNATURES AS A GUIDE TO MEDICAL DIAGNOSTICS AND TREATMENT
How to take the guesswork out of healing with photodynamic (light) therapy
(A Biochromatic, Light-Based Medical Diagnostic and Treatment Protocol)
By Jay Schorr
PREMISE:
Each chemical reaction emits energy, which in turn has a unique chromatic (color) fingerprint; a spectral emission.
On the cellular level, we could ‘photograph’ and catalog these chemical reactions and corresponding chromatic signatures in and between cells, spanning both healthy and pathogenically challenged cells. We could then establish a database (baseline guide) of cellular chromatic fingerprints under normal and diseased states.
We could use these light images as a guide to reverse the aberrational chromatic sequence of the diseased cells – by subjecting (exposing) the diseased cells to the appropriate chromatic fingerprint (light wave length/frequency/photonic content) – to ‘repair’ or cure the diseased cells.
SUMMARY:
Healthy and aberrational cellular (chemical) interactions produce corresponding chromatic fingerprints. By photographing and cataloging all chromatic signatures of both healthy and diseased cells (system and/or organ specific), we can establish a baseline of ‘healthy’ chromatic signatures.
Using the database information as a guide, we can then subject the diseased cells to the appropriate ‘healthy’ chromatic fingerprints – photodynamic therapy consisting of the appropriate lightwaves/frequencies as determined by the baseline data – to repair and/or replace pathogenically challenged cells to restore systemic homeostasis.
NOTE: By analogy, what we’ve created with this model is the cellular chromatic equivalent of the Genome Project. A mapping-out – or schematic – of the body’s chromatic signatures (system and organ specific) for both healthy and diseased states. But unlike the results of the Genome Project, the database of chromatic signatures will not only reveal systemic components, but the therapeutic answers, as well.
VALUE PROPOSITION
With its groundbreaking concept, Biochromatics has created a truly unique value proposition that addresses healthcare consumer needs by offering a comprehensive, self-contained diagnostic/treatment paradigm spanning virtually every medical specialty.
Consumer demand for medical diagnostic and treatment technologies has exceeded current technological advances. The Biochromatics protocol not only fills the gap between consumer demand and reliable, cost-efficient diagnostic and treatment alternatives, it supplants many of today’s default medical technologies. As the protocol is developed, perfected, tested and brought into the mainstream, it will become a ubiquitous and indispensible part of day-to-day medical practice.
By affording consumers a cost-effective, comprehensive diagnostic/treatment option that no other company in the world offers, Biochromatics can blend core competencies to create a value proposition that is greater than the sum of the parts.
COLLECTIVE BUSINESS MODEL
Biochromatics envisions utilizing a Collective Business Model under which a collaborative effort with our consultants – leading photonics researchers in university/academic settings – would enable a cost-effective R&D effort. Additionally, partnering with these academic consultants and their affiliated state-of-the-art photonics and medical research facilities allows for efficacious clinical research and chromatic database compilation.
The Collective Business Model enables us to cull from the best and the brightest minds in the photonics, medical and related fields to develop the Biochromatics signature database as well as the requisite imaging technologies.
Biochromatics would like to leverage today’s optical imaging technology – both off-the-shelf and in the R&D stage – in developing an imaging system capable of detecting cellular heat (chromatic) signatures (organ- and system-specific) without aid of a potentially biasing luminescent agent, either chemical-/laser-/ and or heat-based.
©2007 Jay Schorr All Rights Reserved Patent Pending
B”H